Skip to content
PubMed This is a summary of 16 peer-reviewed journal articles Updated
Neurology · Chronic Inflammatory Demyelinating Polyradiculoneuropathy

Understanding Your Diagnostic Reports

At a Glance

CIDP is diagnosed by combining symptoms with nerve conduction and EMG findings, spinal-fluid results, imaging, and selected blood tests. No single result proves or rules out CIDP, and age, technical factors, and other conditions can affect interpretation.

Understanding your diagnostic reports is a key step in managing CIDP. Because this condition is rare and complex, doctors follow a strict set of international guidelines—the 2021 EAN/PNS criteria—to ensure an accurate diagnosis [1]. A diagnosis is not based on a single test but on a “puzzle” of clinical symptoms, electrical measurements, and blood work [2].

The Nerve Conduction Study (NCS) and EMG

Electrodiagnostic testing involves both a Nerve Conduction Study (NCS), which uses small electrical shocks on the skin to measure nerve speed, and a needle EMG, which places a tiny needle into the muscle to record its activity. In CIDP, the primary finding is demyelination—damage to the protective “insulation” of the nerve [3]. Note that temperature, entrapment sites, height, age, and technical factors can all affect these results.

When reading your NCS report, you may see these technical terms:

  • Slowed Conduction Velocity: This means the electrical signal is traveling slower than normal because the insulation is thin or missing [4].
  • Conduction Block: The signal is not just slow; it actually gets “stuck” or significantly weakened at a specific point along the nerve [5].
  • Temporal Dispersion: This occurs when the individual fibers in a single nerve are damaged at different rates, causing the electrical signal to arrive at the muscle in a “smear” rather than one strong pulse [5].
  • Distal Latency: This measures how long it takes for a signal to jump from the nerve to the muscle. A “prolonged” latency suggests damage near the ends of the nerves [4].

It is important to distinguish demyelination from axonal loss, where the core “wire” itself is damaged. While a study showing predominantly axonal damage should prompt an expert review of the diagnosis, secondary axonal loss is actually very common in long-standing CIDP and does not automatically disprove the disease [4][6].

The Lumbar Puncture (Spinal Tap)

A lumbar puncture analyzes the cerebrospinal fluid (CSF) that surrounds your brain and spinal cord. Doctors look for a pattern called albuminocytologic dissociation [7].

  • What it means: An elevated level of protein in the fluid, but a low (normal) number of white blood cells [7].
  • Its role: This finding is supportive, not definitive. Many conditions (including normal aging) can cause slightly elevated protein [8]. Current guidelines recommend using age-adjusted protein limits rather than a one-size-fits-all number [7][8].

Imaging: Ultrasound and MRI

In some cases, your doctor may use Nerve Ultrasound or MRI (specifically MR Neurography) to look at your nerves.

  • What they look for: In CIDP, the nerves often become physically swollen or enlarged (called hypertrophy) as the body repeatedly tries to repair the damaged myelin [9].
  • Where they look: MRI is particularly good at seeing the “roots” of the nerves near your spine, which are difficult to reach with standard electrical tests [10][11].

Clinician-Directed Blood Tests

To be certain of a CIDP diagnosis, your doctor may run tests to rule out “look-alike” conditions. These tests are selected based on your specific symptoms, and not every patient needs all of them.

  1. SPEP and IFE: Serum Protein Electrophoresis (SPEP) and Immunofixation (IFE) look for abnormal proteins that could indicate a related blood disorder or POEMS syndrome [12]. This is commonly tested.
  2. Free Light Chain Assay and Anti-MAG testing: These may be ordered depending on whether you have an IgM monoclonal protein [13].
  3. Nodal/Paranodal Antibodies: Tests for specific antibodies (like anti-NF155, anti-CNTN1, or anti-CASPR1) [14]. This is especially considered if you have a significant hand tremor, poor balance, or if you have not responded well to standard IVIg treatment [15][16]. A negative antibody test does not exclude CIDP.

If your reports show “possible CIDP,” these extra tests can help your doctor support the diagnosis after other causes are ruled out [2].

Common questions in this guide

How is CIDP diagnosed from my test results?
CIDP is diagnosed by combining your symptoms and examination with nerve conduction studies and EMG. Spinal-fluid analysis, nerve imaging, and selected blood or antibody tests can support the diagnosis or help rule out conditions that look similar. No single test confirms CIDP on its own.
What do slowed nerve signals or conduction block mean on a CIDP report?
These findings can indicate damage to myelin, the protective covering around a nerve. Slowed conduction means signals travel more slowly, while conduction block means a signal becomes markedly weakened or stops at part of the nerve. Doctors also consider temporal dispersion and distal latency, along with technical factors that can affect the results.
Does axonal loss mean I do not have CIDP?
No. Axonal loss can develop as a secondary effect of long-standing CIDP, so it does not automatically disprove the diagnosis. If testing shows mainly axonal damage, a neurology expert may need to review the findings and reconsider other possible causes.
What does high protein in spinal fluid mean for CIDP?
A high protein level with few or no extra white blood cells is a pattern called albuminocytologic dissociation, and it can support CIDP. It is not definitive because aging and other conditions can also raise spinal-fluid protein. Doctors should use age-adjusted reference ranges when interpreting the result.
Why are blood and antibody tests ordered when CIDP is suspected?
Blood tests such as SPEP, or serum protein electrophoresis, and IFE, or immunofixation, can look for abnormal proteins and conditions that mimic or accompany CIDP, including POEMS syndrome. Depending on the findings, doctors may also order free light-chain, anti-MAG, or nodal and paranodal antibody tests. A negative antibody result does not rule out CIDP.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Does my Nerve Conduction Study (NCS) meet the 2021 EAN/PNS criteria for demyelination in at least two separate nerves?
  2. 2.Was the slowing in my nerves found in areas of common compression, like the wrist, or in 'non-compressible' sites that are more typical of CIDP?
  3. 3.Given my CSF results, were age-adjusted reference ranges used to interpret my protein levels?
  4. 4.Can you confirm that my blood work included immunofixation (IFE) and not just a standard electrophoresis (SPEP)?
  5. 5.Based on my symptoms (like tremor or balance issues), should we test for nodal/paranodal antibodies like NF155 or CNTN1?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (16)
  1. 1

    European Academy of Neurology/Peripheral Nerve Society guideline on diagnosis and treatment of chronic inflammatory demyelinating polyradiculoneuropathy: Report of a joint Task Force-Second revision.

    Van den Bergh PYK, van Doorn PA, Hadden RDM, et al.

    European journal of neurology 2021; (28(11)):3556-3583 doi:10.1111/ene.14959.

    PMID: 34327760
  2. 2

    Tips in navigating the diagnostic complexities of chronic inflammatory demyelinating polyradiculoneuropathy.

    Lewis RA, van Doorn PA, Sommer C

    Journal of the neurological sciences 2022; (443()):120478 doi:10.1016/j.jns.2022.120478.

    PMID: 36368137
  3. 3

    Immune-Mediated Neuropathies: Pathophysiology and Management.

    Shastri A, Al Aiyan A, Kishore U, Farrugia ME

    International journal of molecular sciences 2023; (24(8)) doi:10.3390/ijms24087288.

    PMID: 37108447
  4. 4

    Significance of aberrant nerve conduction in hereditary transthyretin amyloidosis.

    Ide T, Yoshikawa M, Suzuyama K, et al.

    Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis 2026; (33(2)):196-204 doi:10.1080/13506129.2026.2613126.

    PMID: 41524533
  5. 5

    The Diagnostic Accuracy of the Second Revision of the European Academy of Neurology/Peripheral Nerve Society Guideline for Diagnosing Chronic Inflammatory Demyelinating Polyradiculoneuropathy.

    van Doorn IN, Baars AE, Wieske L, et al.

    European journal of neurology 2026; (33(8)):e70726 doi:10.1111/ene.70726.

    PMID: 42549490
  6. 6

    Electrodiagnostic errors contribute to chronic inflammatory demyelinating polyneuropathy misdiagnosis.

    Allen JA, Ney J, Lewis RA

    Muscle & nerve 2018; (57(4)):542-549 doi:10.1002/mus.25997.

    PMID: 29053880
  7. 7

    What Is in the Literature.

    Bromberg MB

    Journal of clinical neuromuscular disease 2020; (22(1)):35-41 doi:10.1097/CND.0000000000000298.

    PMID: 32833722
  8. 8

    Updated cerebrospinal fluid total protein reference values improve chronic inflammatory demyelinating polyneuropathy diagnosis.

    Breiner A, Bourque PR, Allen JA

    Muscle & nerve 2019; (60(2)):180-183 doi:10.1002/mus.26488.

    PMID: 30989684
  9. 9

    Use of Magnetic Resonance Neurography for Evaluating the Distribution and Patterns of Chronic Inflammatory Demyelinating Polyneuropathy.

    Su X, Kong X, Lu Z, et al.

    Korean journal of radiology 2020; (21(4)):483-493 doi:10.3348/kjr.2019.0739.

    PMID: 32193896
  10. 10

    Nerve ultrasound can identify treatment-responsive chronic neuropathies without electrodiagnostic features of demyelination.

    Goedee HS, Herraets IJT, Visser LH, et al.

    Muscle & nerve 2019; (60(4)):415-419 doi:10.1002/mus.26629.

    PMID: 31294858
  11. 11

    Role of Imaging in Chronic Inflammatory Demyelinating Polyneuropathy: A Systematic Review.

    Tozza S, Cassano E, Erra C, et al.

    European journal of neurology 2025; (32(6)):e70226 doi:10.1111/ene.70226.

    PMID: 40452261
  12. 12

    History, Diagnosis, and Management of Chronic Inflammatory Demyelinating Polyradiculoneuropathy.

    Dyck PJB, Tracy JA

    Mayo Clinic proceedings 2018; (93(6)):777-793 doi:10.1016/j.mayocp.2018.03.026.

    PMID: 29866282
  13. 13

    Optimizing Anti-Myelin-Associated Glycoprotein and IgM-Gammopathy Testing for Neuropathy Treatment Evaluation.

    Klein CJ, Triplett JD, Murray DL, et al.

    Neurology 2024; (103(11)):e210000 doi:10.1212/WNL.0000000000210000.

    PMID: 39499873
  14. 14

    Antibodies to neurofascin, contactin-1, and contactin-associated protein 1 in CIDP: Clinical relevance of IgG isotype.

    Cortese A, Lombardi R, Briani C, et al.

    Neurology(R) neuroimmunology & neuroinflammation 2020; (7(1)) doi:10.1212/NXI.0000000000000639.

    PMID: 31753915
  15. 15

    Antibodies against the node of Ranvier: a real-life evaluation of incidence, clinical features and response to treatment based on a prospective analysis of 1500 sera.

    Delmont E, Brodovitch A, Kouton L, et al.

    Journal of neurology 2020; (267(12)):3664-3672 doi:10.1007/s00415-020-10041-z.

    PMID: 32676765
  16. 16

    Clinical, Electrophysiologic, and Pathologic Features of Anti-Contactin-Associated Protein 1 Autoimmune Nodopathy.

    Tashiro T, Ogata H, Fukami Y, et al.

    Neurology 2025; (105(9)):e214143 doi:10.1212/WNL.0000000000214143.

    PMID: 41052376

This page explains CIDP diagnostic reports for informational purposes only and does not constitute medical advice. Your neurologist should interpret your reports, symptoms, and results together.

Get notified when new evidence is published on polyneuropathy, inflammatory demyelinating, chronic.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.